Quick Takeaways
- Invus Global Management, LLC filed SCHEDULE 13G/A for Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX).
- Disclosed ownership: 2.5%.
- Date of event: 31 Mar 2026.
Quoteable Key Fact
"Invus Global Management, LLC disclosed 2.5% ownership in Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX) on 31 Mar 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 0.4% | 60,998 | 60,998 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 0.4% | 60,998 | 60,998 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 0.4% | 60,998 | 60,998 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 2.5% | 427,141 | 427,141 | 0 | /s/ Raymond Debbane | Raymond Debbane |